Unknown
PHASE4
INTERVENTIONAL
NCT02281266
Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Efficacy and safety of Thymalfasin adjuvant therapy in HBV-related HCC after curative resection.
Detailed Description
Multi-center, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Thymalfasin Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma After Curative Resection.
Interventions
Name:
curative resection
Type:
PROCEDURE
Description:
Name:
thymalfasin
Type:
DRUG
Description:
1.6mg twice a week, 12 months
Name:
nucleoside analog (suggest to use entecavir)
Type:
DRUG
Description:
Primary Outcomes
Measure:
Recurrence-free Survival
TimeFrame:
2-year
Description:
Trial Information
NCT ID
NCT02281266
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Jia Fan
Last Updated
December 15, 2025